Denied: How a Medicare Advantage Plan Failed a Patient Despite Industry Pledges
A 70-year-old patient faced life-threatening hurdles after her Medicare Advantage plan denied coverage for essential immunodeficiency medication.
From Marathon Runner to Hospital Bed
Margaret Hvatum, a 70-year-old computer science professor from Ladue, Missouri, maintains an active lifestyle that would challenge people half her age. In January, she completed a grueling series of endurance events, including a marathon, only to find herself hospitalized weeks later. Hvatum suffers from primary immunodeficiency, a condition that leaves her body unable to effectively combat infections, requiring consistent treatment with Hizentra—a plasma-based antibody product.
For over a decade, Hvatum managed her condition by self-administering this medication at home. However, her transition to a Humana Medicare Advantage plan at the start of the year triggered a series of administrative roadblocks. Her previous authorization did not carry over, and Humana denied her request for the life-sustaining drug. The financial stakes were immense: without insurance, a 28-day supply of the medication costs $8,141.94.
The Prior Authorization Trap
When the medication denials began, Hvatum’s health deteriorated rapidly. She developed a urinary tract infection that required an emergency room visit and an overnight stay, resulting in $18,000 in hospital bills that Humana initially refused to cover. The insurer argued that her condition did not necessitate inpatient care, despite medical advice suggesting that patients with her immunodeficiency are at high risk for rapid decline.
This experience highlights a growing tension between private insurers and Medicare beneficiaries. While major insurance companies, including Humana, signed a public pledge to reform prior authorization processes—specifically promising to honor existing approvals for 90 days during plan switches—these commitments often exclude prescription drugs. Humana maintains that their review process is a vital safety check to ensure quality care and taxpayer responsibility, yet critics argue these denials are primarily tools for profit maximization.
A Cycle of Denials and Appeals
Data from KFF reveals that Medicare Advantage plans processed approximately 53 million prior authorization requests in 2024. While Hvatum eventually succeeded in overturning her denials through the appeals process, the victory felt hollow. Her approval for Hizentra came with an expiration date, forcing her to confront the prospect of recurring battles for coverage.
Following a stroke in March, Hvatum faced further pushback from Humana regarding her hospital admission. Although the insurer again reversed its decision following an appeal, the pattern of swift denials followed by delayed approvals has taken a psychological toll. Now, Hvatum and her husband are exploring the possibility of moving to Norway, seeking a healthcare system that offers greater stability than her current private insurance arrangement.
Recent Developments
Patients across the country are closely watching how insurance providers handle prior authorization requests amidst ongoing scrutiny. Recent breaking news indicates that federal regulators are under pressure to provide the latest updates on oversight policies to protect beneficiaries. You can follow all developments instantly on MedicareTicker.com.
Related Topics
🔹 Medicare Advantage 🔹 Prior Authorization 🔹 Patient Advocacy 🔹 Insurance Denials 🔹 Health Policy 🔹 Healthcare Reform
Breaking-news News
This category provides breaking news and the latest updates on critical shifts within the healthcare industry. Our coverage ensures readers stay informed with live reporting on policy changes, insurance disputes, and regulatory actions featured on MedicareTicker.com.
Frequently Asked Questions
What is a prior authorization in Medicare Advantage?
It is an administrative process where insurance companies require patients or their doctors to obtain approval before a specific medication or procedure is covered. If not granted, the patient may be responsible for the full cost of the treatment.
Why do insurers deny coverage for medically necessary drugs?
Insurers often cite quality control and cost-containment as reasons for denials. However, experts note that these denials help firms maintain profit margins by limiting the total amount of care covered under their plans.
Are patients successful in appealing these denials?
Yes, data shows that a significant majority of appeals for Medicare Advantage denials are eventually overturned. However, the process is notoriously exhausting, often discouraging many patients from pursuing their rights.